Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 208 in metastatic castration-resistant prostate cancer
NCT02420587Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2014
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amg‑208 in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Planned start Oct 2014; status: withdrawn.
02
Drugs
amg‑208
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02420587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420587.